Specialty Matched Consultant Advisory Panel review 12/2012. Removed the following statement from the "When not Covered" section: "Urinary bladder tumor markers are considered investigational for screening for bladder cancer in asymptomatic patients." Revised statement in the "When Covered" section: "The following urinary bladder tumor markers may be considered medically necessary as an adjunct in the diagnosis of bladder cancer only in conjunction with current standard diagnostic procedures for patients who have an atypical or equivocal cytology..." Revised headers in "When Covered" from "Bladder cancer monitoring" to "Bladder cancer surveillance" and "Initial Diagnosis" to "Initial Evaluation." Medical Director review 3/2013.

New Evidence Based Guideline developed. Genetic testing for a PTEN mutation is recommended to confirm the diagnosis when a patient has clinical signs of a PTEN hamartoma tumor syndrome. Genetic testing for a PTEN mutation is recommended in a first -degree relative of a proband with a known PTEN mutation. Genetic testing for a PTEN mutation is not recommended for all other indications, including, but not limited to, prenatal testing. Medical Director review 3/2013.

Description section updated. "When Recommended" section revised to state: "Ventricular assist devices with FDA approval or clearance, including humanitarian device exemptions, are recommended as a bridge to heart transplantation in children 16 years old or younger who are currently listed as heart transplantation candidates and not expected to survive until a donor heart can be obtained, or are undergoing evaluation to determine candidacy for heart transplantation." Deleted Q0505 and added Q0507, Q0508, and Q0509 to Billing/Coding section. References updated. Medical Director review 3/2013.